Fundraising FoxFate Therapeutics
NASDAQ: FATESan Diego, US · Delaware corporation · 5 known investors
Find your way into Fate Therapeutics
287 people in our graph can introduce you to the Fate Therapeutics team.
Sign up to see every warm intro you have to Fate Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Fate Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer. The company is conducting clinical trials on product candidates under strict regulatory and ethical standards.
Founders & leadership
CW
Christian WeyerExecutive
JS
J. Scott WolchkoExecutive
B(
Bahram (Bob) ValamehrPresident & Chief Executive OfficerBahram Valamehr is President and CEO of Fate Therapeutics, which develops cellular immunotherapies based on pluripotent stem cell technology for treating cancer and autoimmune diseases.
Board
AN
Amir NashatBoard Member2008–2020Entrepreneur partner at Polaris Partners focused on healthcare investing and portfolio company executive roles
JM
John MendleinBoard director
WR
William RastetterBoard director
ME
Mark EnyedyBoard director
TC
Timothy CoughlinBoard director
RE
Robert EpsteinBoard director
Investors · 5
Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Venrocklisted by VenrockPalo Alto · $500K – $10M
How we know: the S-1 prospectus · Not right? Tell us
Fidelity InvestmentsreportedBoston
How we know: the S-1 prospectus · Not right? Tell us
OVP Venture PartnersreportedSeattle
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$175M disclosed across 5 rounds · 2015–2020
▶$50MraisedJul 2020 · 1 investors · BiotechnologyRule 506(b)
▶$50MraisedJul 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shefali AgarwalDirector
- Cindy TahlExecutive Officer
- Karin JoossDirector
- Robert HershbergDirector
- J. Scott WolchkoExecutive Officer, Director
- William RastetterDirector
- Timothy CoughlinDirector
- Michael LeeDirector
- John MendleinDirector
- Robert EpsteinDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedApr 2020 · 1 investors · BiotechnologyRule 506(b)
▶$50MraisedApr 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert EpsteinDirector
- J. Scott WolchkoExecutive Officer, Director
- Shefali AgarwalDirector
- Michael LeeDirector
- John MendleinDirector
- Cindy TahlExecutive Officer
- William RastetterDirector
- Karin JoossDirector
- Timothy CoughlinDirector
- Amir NashatDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$56.7MraisedDec 2016 · 21 investors · BiotechnologyRule 506(b)
▶$56.7MraisedDec 2016 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JOHN MENDLEINDirector
- ROBERT S. EPSTEINDirector
- CINDY TAHLExecutive Officer
- J. SCOTT WOLCHKOExecutive Officer, Director
- MARK J. ENYEDYDirector
- WILLIAM RASTETTERDirector
- TIMOTHY P. COUGHLINDirector
- CHRIS STORGARDExecutive Officer
- AMIR NASHATDirector
- STEWART ABBOTExecutive Officer
- DANIEL D. SHOEMAKERExecutive Officer
- Offering amount
- $56.7M
- Amount sold
- $56.7M
- Sales commissions
- $1.7M
- Placement agents
- LEERINK PARTNERS LLC
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.3MraisedAug 2016 · 4 investors · BiotechnologyRule 506(b)
▶$10.3MraisedAug 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DANIEL D. SHOEMAKERExecutive Officer
- ROBERT S. EPSTEINDirector
- WILLIAM RASTETTERDirector
- JOHN MENDLEINDirector
- STEWART ABBOTExecutive Officer
- MARK J. ENYEDYDirector
- TIMOTHY P. COUGHLINDirector
- AMIR NASHATDirector
- CHRIS STORGARDExecutive Officer
- J. SCOTT WOLCHKOExecutive Officer, Director
- CINDY TAHLExecutive Officer
- Offering amount
- $10.3M
- Amount sold
- $10.3M
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2015 · 1 investors · BiotechnologyRule 506(b)
▶$8MraisedMay 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amir NashatDirector
- John MendleinDirector
- Christian WeyerExecutive Officer, Director
- William RastetterDirector
- J. Scott WolchkoExecutive Officer
- Mark EnyedyDirector
- Daniel ShoemakerExecutive Officer
- Timothy CoughlinDirector
- Robert EpsteinDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$115Mvaluation at IPOOct 2013 · $6.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
5 people who came through Fate Therapeutics went on to found or lead other companies.
Amir NashatDirectorFounded Jnana Therapeutics +3Paul GraysonPresident and CEOFounded Radionetics +1Andreas NiethammerVice President Clinical Development & Translational MedicineFounded VaximmZachary D. HornbySenior Director, Business DevelopmentFounded Boundless BioPeter FlynnSenior Vice President, Early Program DevelopmentFounded Artivabio
Related companies · 2
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Fate Therapeutics.
In the news
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis - BioSpacebiospace.com · Aug 2026Frequently asked questions
- What does Fate Therapeutics do?
- Fate Therapeutics develops investigational cellular immunotherapies to treat autoimmune diseases and cancer. The company is conducting clinical trials on product candidates under strict regulatory and ethical standards.
- Who are Fate Therapeutics's investors?
- Fate Therapeutics's investors include Sanofi Ventures, Venrock, Fidelity Investments, OVP Venture Partners, Polaris Partners.
- How much funding has Fate Therapeutics raised?
- Fate Therapeutics has disclosed $175M raised across 5 rounds.
- Where is Fate Therapeutics headquartered?
- Fate Therapeutics is headquartered in San Diego, US.